Fu­ji­film out­lays whop­ping $850M for its Diosynth CM­DO wing, look­ing to rapid­ly scale cell cul­ture pro­duc­tion

Fu­ji­film Diosynth Biotech­nolo­gies is on a spend­ing spree and not stop­ping yet.

The Japan­ese firm is adding man­u­fac­tur­ing ca­pa­bil­i­ty at its core CD­MO wing by pump­ing $850 mil­lion in­to lo­ca­tions in the US and UK, it said in a re­lease.

Gene ther­a­py ca­pac­i­ty in the UK will in­crease 10-fold, cell cul­ture ca­pac­i­ty will be tripled and mi­cro­bial fer­men­ta­tion out­put will be dou­bled at the 5,000-liter fa­cil­i­ty. In the US, cell cul­ture pro­duc­tion for re­com­bi­nant vac­cines will dou­ble. These two ex­pan­sions will start in 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER